drugset / Trial / NCT00160654

Open Label Safety and Efficacy Study of Levetiracetam in Patients With Epilepsy

NCT00160654

Phase 4 Completed 251 enrolled UCB Pharma
NaSingle-groupOpen-labelTreatment

Summary

Community based study assessing safety and efficacy of levetiracetam in partial onset seizures. The optimal dose in daily clinical practice will be used.

Timeline

Start
2003-11-24
Primary completion
2006-12-12
Completion
2006-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified Oral

Indications